



04-10-53

Attorney Docket No. 037003-0275543
Client Ref. No.: 1991-30-0019CP4C1

1042

S

P#11

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Hanna, et al.

Serial No. 09/612,914

Filed: July 10, 2000

For: RECOMBINANT ANTI-CD4
ANTIBODIES OR HUMAN
THERAPY

Art Unit: 1642

Examiner: Yaen, C.

Certificate of Mailing

I, Patricia Munoz, hereby certify that this paper or fee is being deposited with the United States Postal Service as Express Mail Post Office to Addressee service (Mailing Label No. EV 159 087 818 US) under 37 C.F.R. § 1.10 on the date indicated below and is addressed to the Hon. Commissioner of Patents and Trademarks, Washington D.C. 20231.

By: Patricia MunozDate: April 8, 2003

RECEIVED

INFORMATION DISCLOSURE STATEMENT

APR 14 2003

TECH CENTER 1600/2900

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the Applicants' duty under 37 C.F.R. §§1.97–98, the following information is brought to the attention of the Examiner. The items are listed on the attached form PTO-1449 and copies of the references are attached for the Examiner's convenience.

Certain of these references were cited in the European Search Report for EP 1 266 965 A3 which is related to the present application in that both claim priority from, *inter alia*, certain earlier filed United States applications. A copy of the European Search Report is attached.

The items identified in this Information Disclosure Statement may or may not be "material" pursuant to 37 CFR §1.56 and the submission thereof by Applicants shall not be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 C.F.R. §1.97(h)), or even qualifies as "prior art" under 35 U.S.C. §102 with respect to this invention unless specifically designated by Applicants as such.

70037085v1

The filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information, as defined in 37 C.F.R. §1.56, exists.

A check in the amount of \$180.00 is enclosed for the required fee. The Commissioner is hereby authorized to charge any fee, including any fee due with this submission, if the attached check(s) is in the wrong amount or otherwise improper or missing, that may be due in connection with this and the attached papers, or with this application during its entire pendency to or to credit any overpayment to Deposit Account 03-3975, Order No. 037003-0275543.

Respectfully submitted,

PILLSBURY WINTHROP LLP

By 
Suzanne L. Biggs
Registration No. 30,158

Dated: April 18, 2003

Address all correspondence to:
11682 El Camino Real, Suite 200
San Diego, CA 92130
Tel: (858) 509-4095
Fax: (858) 509-4010

FORM PTO-1449 (modified)
 To: U.S. Department of Commerce
 (PMB FORM PAT 1449)
 Patent and Trademark Office

APR 08 2003

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Date: April 8, 2003

Page **1** of **1**

Atty. Dkt. No.		Client Ref.
	037003-0275543	1991-30-0019CP4C1

Applicant: Hanna, et al.

Appln. No.: 09/612,914

Filing Date: July 10, 2000

Examiner: Yaen, C. Group Art Unit: 1642

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
AR						

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name		English Abstract	Translation Readily Available		
						Enclosed	No	Enclos	No
BR	0 523 949 A1	07/1992	EP	Crowe, et al.					
CR	1 266 965 A2	12/2002	EP	Newman, et al.					
DR	1 266 965 A3	01/2003	EP	Newman, et al.					
ER									

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

✓ FR	Combriato, G., et al., V λ and J λ -C λ gene segments of the human immunoglobulin λ light chain locus are separated by 14 kb and rearrange by a deletion mechanism, <i>Eur. J. Immunol.</i> 21:1513-1522 (1991)	RECEIVED APR 14 2003 TECH CENTER 1600/2900
✓ GR	Houghton, A., et al., Monoclonal antibodies: potential applications to the treatment of cancer, <i>Seminars in Oncology</i> , 13(2):165-179 (1986)	
✓ HR	Hughes-Jones, N., et al., Nucleotide sequences and three-dimensional modelling of the V H and V L domains of two human monoclonal antibodies specific for the D antigen of the human Rh-blood-group system, <i>Biochem. J.</i> 268:135-140 (1990)	
✓ IR	Riechmann, L., et al., Reshaping human antibodies for therapy, <i>Nature</i> 332(6162):323-327 (Mar. 24, 1988)	
✓ JR	Schroeder, H., et al., Early restriction of the human antibody repertoire, <i>Science, New Series</i> , 238(4828):791-793 (Nov. 6, 1987)	
✓ KR	Stephens, D.M., et al., Antibodies are produced to the variable regions of the external envelope glycoprotein of human immunodeficiency virus type 1 in chimpanzees infected with the virus and baboons immunized with a candidate recombinant vaccine, <i>Journal of General Virology</i> , 73:1099-1106 (1992)	
✓ LR	Truneh, A., et al., Humoral response of cynomolgus macaques to human soluble CD4: antibody reactivity restricted to xeno-human determinants, <i>Cellular Immunology</i> 131:98-108 (1990)	
✓ MR	Van Meurs, G.J.E., et al., Production of primate monoclonal antibodies, <i>Journal of Immunological Methods</i> , 95:123-128 (1986)	
✓ NR	Watanabe, M., et al., Immunization of simian immunodeficiency virus-infected rhesus monkeys with soluble human CD4 elicits an antiviral response, <i>Proc. Natl. Acad. Sci. USA</i> , 88:4616-4620 (Jun. 1991)	

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.